Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $74.86

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have received an average rating of "Buy" from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued a report on the stock in the last year is $74.86.

JSPR has been the subject of a number of research reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. JMP Securities reiterated a "market outperform" rating and issued a $70.00 price target on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. Royal Bank of Canada decreased their price target on Jasper Therapeutics from $70.00 to $68.00 and set an "outperform" rating for the company in a research note on Wednesday, August 14th. Evercore ISI reiterated an "outperform" rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Monday, August 26th. Finally, HC Wainwright reiterated a "buy" rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Thursday, October 24th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of JSPR. Russell Investments Group Ltd. acquired a new position in Jasper Therapeutics in the first quarter worth about $2,343,000. Bank of New York Mellon Corp acquired a new position in Jasper Therapeutics in the second quarter worth about $740,000. American Century Companies Inc. raised its position in Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company's stock worth $322,000 after purchasing an additional 3,032 shares in the last quarter. Ikarian Capital LLC acquired a new position in Jasper Therapeutics in the first quarter worth about $3,088,000. Finally, Wolff Wiese Magana LLC acquired a new position in Jasper Therapeutics in the third quarter worth about $59,000. Institutional investors and hedge funds own 79.85% of the company's stock.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock traded down $1.16 during midday trading on Tuesday, reaching $23.57. The stock had a trading volume of 80,121 shares, compared to its average volume of 173,159. The stock's 50-day simple moving average is $19.99 and its 200 day simple moving average is $20.92. Jasper Therapeutics has a twelve month low of $4.00 and a twelve month high of $31.01. The stock has a market capitalization of $355.91 million, a PE ratio of -5.22 and a beta of 2.19.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.12. Equities analysts predict that Jasper Therapeutics will post -4.19 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.